Allogene Therapeutics
16 articles with Allogene Therapeutics
-
South San Francisco-based Allogene Therapeutics inked a research collaboration deal with Stanford University to work on a novel nucleic acid delivery system for CAR-T therapy.
-
BioSpace Movers and Shakers, Aug. 9
8/9/2019
Biopharma companies strengthen their senior leadership teams and boards of directors. -
ALLOGENE THERAPEUTICS APPOINTS RAFAEL G. AMADO, M.D. AS EXECUTIVE VICE PRESIDENT OF RESEARCH AND DEVELOPMENT AND CHIEF MEDICAL OFFICER
8/6/2019
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced the appointment of Rafael G. Amado, M.D., as Executive Vice President of Research and Development and Chief Medical Officer
-
How can you selectively target and destroy cancerous T-cells using other T-cells? This question has plagued researches hoping to apply chimeric antigen receptor (CAR) T-cell therapies to T-cell cancers.
-
While this type of personalized therapy is revolutionizing cancer treatment and healthcare, it has some formidable limitations.
-
Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
-
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
-
If you’re in the pharma or biotech industry and are looking for work, multiple companies have announced expansions of their employee pool over the past few days. BioSpace rounds up a few of the announcements.
-
Allogene Therapeutics Enters Lease to Build Manufacturing Facility to Develop and Commercialize Allogeneic CAR T (AlloCAR T™) Therapies
2/20/2019
• State-of-the-Art Manufacturing Facility to be Located in the San Francisco East Bay Area • Allogene Committed to Advanced Cell Manufacturing for Long-Term Clinical and Commercial AlloCAR T™ Production
-
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
-
Although the size of the IPO is one aspect of determining the success of a company’s public launch, it’s not the only metric. How the stock does in the ensuing months is a very important consideration.
-
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
-
7 Biotech Trends to Look Out for in 2019
12/26/2018
As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle. -
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
-
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
-
A summary of IPOs from companies in the biotech and pharma world since Oct. 1, 2018.